Pharma Technology Inc. Moves to Larger Facility
PTI moved to a new facility in Belgium that will house its headquarters and a R&D center for tablet dedusting, capsule polishing, and testing technology.
Pharma Technology Inc. (PTI), which produces tablet dedusters and capsule polishers combined with metal detectors and loading systems for pharmaceutical solid dose production, is moving its headquarters to a greenfield site half a mile from its current home in Nivelles, Belgium, the company announced in a Nov. 28, 2017 press release. At 60,000 ft2, the new facility is twice the size of the former facility.
The new facility will have a large R&D center for developing tablet dedusting, capsule polishing, and oral solid-dosage drug testing technology. The new facility also doubles manufacturing capacity and increases stocking space. A fully equipped demonstration lab will accommodate customer tests, factory acceptance testing, and special projects with containment (occupational exposure band 3) capacity. Leading up to the move, PTI has hired more than a dozen workers to bring its personnel count to approximately 75. A formal inauguration for the new plant is planned for March 2018.
Source: PTI
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
